Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
Schizophrenia
Brexpiprazole Provides Short- and Long-Term Benefits in Schizophrenia
The goal of the researchers was to describe the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) “Marder factors.”
Undervaccination for COVID-19 Found for Individuals With Schizophrenia
Individuals with schizophrenia are undervaccinated against COVID-19 compared with age- and gender-matched controls in Israel.
Novel Glycine Transporter Inhibitor Gets Breakthrough Tx Status for Cognitive Impairment With Schizophrenia
The designation is based on results from a phase 2 trial that evaluated the efficacy and safety of 4 different doses of BI 425809 orally once daily in adults with CIAS for 12 weeks.
Dexmedetomidine Oral Film Under Review for Agitation With Schizophrenia, Bipolar Disorder
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
Recommendations for Long-Acting Injectable Antipsychotics in Schizophrenia
Several clinical practice guidelines on the treatment of schizophrenia have recently been updated in the United States. In order to understand the recommendations of current clinical practice guidelines, the study authors conducted a systematic literature review.
Study Shows Patients with Schizophrenia Have Higher Rates of Cardiovascular Autonomic Neuropathy
Researchers compared standard cardiovascular autonomic reflex tests results among patients with schizophrenia and psychiatrically healthy controls at a university hospital in Denmark.
History of Depression, Anxiety Inversely Correlates With Age of Onset in Alzheimer Disease
There may be an association between a history of psychiatric disorders in patients and age of onset of Alzheimer disease.
Severe Mental Illness Tied to Higher Risk for Heart Attack Death
People with a severe mental illness (SMI) are more likely to die following a heart attack than those without a psychiatric diagnosis.
Pharmacogenetic Considerations for Psychotropic Drugs
Dosing adjustments and precautions for pharmacogenetic variations with psychotropic medications.
- Loading...
Loading...
Next post in News
Loading... 
Loading...